THAR Stock Overview
A clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Tharimmune, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.40 |
| 52 Week High | US$163.09 |
| 52 Week Low | US$2.75 |
| Beta | 1.52 |
| 11 Month Change | -34.24% |
| 3 Month Change | -49.20% |
| 1 Year Change | -97.54% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.74% |
Recent News & Updates
Shareholder Returns
| THAR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.7% | -1.4% | 1.8% |
| 1Y | -97.5% | 10.4% | 24.0% |
Return vs Industry: THAR underperformed the US Biotechs industry which returned 8.2% over the past year.
Return vs Market: THAR underperformed the US Market which returned 23.6% over the past year.
Price Volatility
| THAR volatility | |
|---|---|
| THAR Average Weekly Movement | 14.6% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: THAR's share price has been volatile over the past 3 months.
Volatility Over Time: THAR's weekly volatility has decreased from 21% to 15% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 3 | Randy Milby | www.tharimmune.com |
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company’s pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2.
Tharimmune, Inc. Fundamentals Summary
| THAR fundamental statistics | |
|---|---|
| Market cap | US$2.61m |
| Earnings (TTM) | -US$8.89m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs THAR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| THAR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$8.89m |
| Earnings | -US$8.89m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.31 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did THAR perform over the long term?
See historical performance and comparison